ATE319458T1 - Medizinische zusammensetzungen zur behandlung von augenerkrankungen - Google Patents

Medizinische zusammensetzungen zur behandlung von augenerkrankungen

Info

Publication number
ATE319458T1
ATE319458T1 AT99940582T AT99940582T ATE319458T1 AT E319458 T1 ATE319458 T1 AT E319458T1 AT 99940582 T AT99940582 T AT 99940582T AT 99940582 T AT99940582 T AT 99940582T AT E319458 T1 ATE319458 T1 AT E319458T1
Authority
AT
Austria
Prior art keywords
eye diseases
treating eye
compositions
medical compositions
ocular tension
Prior art date
Application number
AT99940582T
Other languages
English (en)
Inventor
Kazuki Endo
Toichi Abiru
Tomokazu Hosokawa
Miwa Misawa
Takashi Konno
Original Assignee
Yamasa Corp
Toa Eiyo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corp, Toa Eiyo Ltd filed Critical Yamasa Corp
Application granted granted Critical
Publication of ATE319458T1 publication Critical patent/ATE319458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT99940582T 1998-09-01 1999-08-31 Medizinische zusammensetzungen zur behandlung von augenerkrankungen ATE319458T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24682698A JP2002173427A (ja) 1998-09-01 1998-09-01 眼疾患治療用医薬組成物

Publications (1)

Publication Number Publication Date
ATE319458T1 true ATE319458T1 (de) 2006-03-15

Family

ID=17154279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940582T ATE319458T1 (de) 1998-09-01 1999-08-31 Medizinische zusammensetzungen zur behandlung von augenerkrankungen

Country Status (11)

Country Link
US (1) US6387889B1 (de)
EP (1) EP1110554B1 (de)
JP (1) JP2002173427A (de)
CN (1) CN1151794C (de)
AT (1) ATE319458T1 (de)
AU (1) AU5446299A (de)
CA (1) CA2342204A1 (de)
DE (1) DE69930271T8 (de)
DK (1) DK1110554T3 (de)
ES (1) ES2259842T3 (de)
WO (1) WO2000012098A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
CA2361614C (en) * 1999-02-01 2008-08-26 University Of Virginia Patent Foundation Compositions for treating inflammatory response
ES2173027B2 (es) * 2000-07-06 2005-12-16 Universidad Complutense De Madrid Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.
AU2001278708A1 (en) 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
WO2002020540A1 (fr) * 2000-09-08 2002-03-14 Toa Eiyo Ltd. Dérivés d'adénosine et leurs applications
EP1434782A2 (de) * 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyladenosine-analoge mit a2a-agonistischer aktivität and diese enthaltende gemische
AU2003234716A1 (en) * 2002-04-10 2003-10-27 Joel M. Linden Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
CA2563123A1 (en) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Selective antagonists of a2a adenosine receptors
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
JP2008285478A (ja) * 2007-04-16 2008-11-27 Santen Pharmaceut Co Ltd アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
WO2011053569A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
IN2015DN00538A (de) * 2012-08-01 2015-06-26 Lewis And Clark Pharmaceuticals Inc
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07106983B2 (ja) * 1987-12-02 1995-11-15 三共株式会社 グリゼオール酸ジエステル誘導体
US5270304A (en) * 1988-11-15 1993-12-14 Yamasa Shoyu Kabushiki Kaisha Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
US5039797A (en) * 1989-10-13 1991-08-13 Yale University 2'-O-(4-benzoyl)benzoyl nucleoside cyclic monophosphate
FR2685918B1 (fr) * 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista

Also Published As

Publication number Publication date
CA2342204A1 (en) 2000-03-09
ES2259842T3 (es) 2006-10-16
DE69930271D1 (de) 2006-05-04
DE69930271T8 (de) 2006-12-28
DK1110554T3 (da) 2006-04-10
EP1110554A4 (de) 2002-02-06
EP1110554B1 (de) 2006-03-08
US6387889B1 (en) 2002-05-14
JP2002173427A (ja) 2002-06-21
CN1315862A (zh) 2001-10-03
WO2000012098A1 (en) 2000-03-09
AU5446299A (en) 2000-03-21
CN1151794C (zh) 2004-06-02
DE69930271T2 (de) 2006-08-24
EP1110554A1 (de) 2001-06-27

Similar Documents

Publication Publication Date Title
ATE319458T1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
ES2062102T3 (es) Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DK1239774T3 (da) Apparat til behandling af öjensygdomme
WO2002009702A8 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
DE60106953D1 (de) Adenosinderivate und deren verwendung
BR9907715A (pt) Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
ATE204752T1 (de) Therapeutische anwendungen von 2',5'- oligoadenylat-derivaten
DE69713648D1 (de) Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
DE69829227D1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
BR0212274A (pt) Uso de estrogênios não-feminilizantes como agentes retinoprotetores para o tratamento de glaucoma
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
CA2219280A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties